Journal de la leucémie
Libre accès
ISSN: 2329-6917
ISSN: 2329-6917
Ghayathri Jeyakumar and Alessandra Ferrajoli
Treatment of Chronic Lymphocytic Leukemia (CLL) is entering a new era. In the last 5 years, several new exciting drugs have entered the realm in hopes for a success in curing the disease. The drugs fall into different classes such as BTK inhibitors, BCL-2 inhibitors, CD 20 Antibody, PI3 Kinase inhibitors, and Syk inhibitors. Numerous studies have shown that these agents have clinical activity both as initial therapy and as treatment of recurrent disease. Novel strategies combining or sequencing new agents with established chemotherapy and chemoimmunotherapies combinations are likely to change the treatment of CLL in the near future.